Amid concerns that the House Democratic leadership is crafting a drug pricing bill that is far too friendly to the pharmaceutical industry, progressives in Congress this week publicly called out House Speaker Nancy Pelosi for writing the legislation in secret and ignoring those who favor a more aggressive approach to lowering out-of-control prescription drug costs.
Rep. Alexandria Ocasio-Cortez (D-N.Y.) was among the progressive Democrats who spoke out Wednesday, telling reporters that the House Democratic leadership has left "most members" completely in the dark on the details of the prescription drug bill.
"That's a problem and it's part of a pattern, I think, where we don't know things until 48 hours before. And then it's like, 'You're either with us or you're against us.'"
—Rep. Alexandria Ocasio-Cortez
"That's a problem and it's part of a pattern, I think, where we don't know things until 48 hours before," Ocasio-Cortez said. "And then it's like, 'You're either with us or you're against us.'"
As Common Dreams reported last month, progressives raised alarm after Pelosi informed Democrats behind closed doors that she is throwing her weight behind a plan that would require the Department of Health and Human Services (HHS) to negotiate the prices of at least 25 drugs each year.
The legislation, according to HuffPost, would do nothing to challenge the monopoly power of pharmaceutical companies.
While the Pelosi-backed plan has not been finalized, Alex Lawson—executive director of the advocacy group Social Security Works—warned that what is known of the proposal is "not even close to sufficient" to address the crisis of soaring drug costs.
Rep. Lloyd Doggett (D-Texas), the sponsor of a more ambitious drug pricing bill, likened Pelosi's approach to the drug pricing legislation with the secretive process the GOP used to craft its Obamacare repeal bill and tax cuts in 2017.
"We have a great history with Republicans where they locked up their healthcare plan so that even Rand Paul couldn't see it, and they held their tax plan to the last minute," Doggett told reporters, "so if there is to be good collaboration here there needs to be more openness."
Under Doggett's bill—which currently has 125 House co-sponsors—Medicare would be permitted to negotiate drug prices. Should drug price negotiations fail, Doggett's bill would require the government to authorize low-cost generics—which, unlike the Pelosi-backed plan, would threaten Big Pharma's monopoly power over the drug market.
Reps. Pramila Jayapal (D-Wash.) and Mark Pocan (D-Wis.), co-chairs of the CPC, joined their fellow progressive lawmakers in raising alarm about Pelosi's secretive process this week.
According to Politico, Jayapal said Tuesday that she "sent Democratic leadership staff a list of questions about their drug pricing work, demanding details after the latest plan raised 'lots of concerns' about whether it would make a significant dent in the prices Americans pay for their prescription drugs."
Pocan told reporters on Tuesday that he simply wants "to make sure that everyone is brought on board" and warned of the consequences of crafting milquetoast legislation that does little to tackling soaring drug costs, an issue that polls near the top of the public's healthcare concerns.
"If we don't address this in a big and bold way, a lot of us should go home and start knitting," Pocan said. "To me, if the conversation ends in two weeks, we got screwed."